
Office of Inspector General

INSPECTOR GENERAL REVIEW OF FISCAL YEAR 2012 DRUG CONTROL FUNDS AND PERFORMANCE SUMMARY REPORTING

Federal Aviation Administration

Report Number: FI-2013-038

Date Issued: February 1, 2013





**U.S. Department of
Transportation**

Office of the Secretary
of Transportation

Office of Inspector General
Washington, DC 20590

February 1, 2013

Ms. U. Jane Sanville
Acting Associate Director, Office of Performance and Budget
Office of National Drug Control Policy
Washington, DC 20503

Dear Ms. Sanville:

This report presents the results of our independent review of the U.S. Department of Transportation, Federal Aviation Administration's (FAA) fiscal year 2012 Drug Control Obligation Summary and Performance Summary reports to the Office of National Drug Control Policy (ONDCP). Both reports are dated January 13, 2013. The reports and our review are required by 21 U.S.C. §1704 (d) and ONDCP's Circular, Annual Accounting and Authentication of Drug Control Funds and Related Performance, of May 2007 (Circular).

The Circular states that when drug-related obligations are less than \$50 million and a detailed accounting would constitute an unreasonable burden, agencies are permitted to submit an alternative report. Because FAA's fiscal year 2012 drug-related obligations were less than \$50 million, FAA submitted an alternative report. In our attestation review, we (1) assessed whether providing a detailed accounting of funds expended on National Drug Control Program activities would constitute an unreasonable burden, and (2) reviewed FAA's report and related management assertions to determine the reliability of those assertions in compliance with the Circular, in all material respects. We conducted our review in accordance with generally accepted Government auditing standards for attestation engagements. However, a review is substantially more limited in scope than an examination, which expresses an opinion on the accuracy of FAA's Drug Control Obligation Summary and Performance Summary reports. Because we conducted an attestation review, we do not express such an opinion.

Drug Control Obligations Summary

We performed review procedures on the accompanying report (Enclosure 1), FAA's fiscal year 2012 Drug Control Obligation Summary, based on criteria specified in the Circular. Our work was limited to inquiries and analytical

procedures appropriate for an attestation review. Specifically, we tested selected accounting internal controls to ensure drug control funds were properly identified in the accounting system. We traced \$17 million of FAA's reported \$26.3 million in drug control obligations to the Department's accounting system. Because FAA is reporting a total amount in drug control obligations—\$26.3 million—below the Circular's \$50 million threshold for full reporting, we believe that full reporting compliance would constitute an unreasonable reporting burden.

Performance Reporting Summary and Assertions

FAA's fiscal year 2012 performance targets were to (1) initiate regulatory investigations on 95 percent of all pilots involved in the sale or distribution of illegal drugs within 30 days of knowledge, a conviction, or notification by law enforcement; (2) ensure the aviation industry conducts random drug and alcohol testing of safety sensitive employees with results not exceeding one percent positives for drugs and one-half percent positives for alcohol; and, (3) conduct 1,650 FAA drug and alcohol inspections of the aviation industry to ensure compliance with Federal regulations. FAA indicated that it met all three performance targets.

We performed review procedures on the accompanying report (Enclosure 2), FAA's fiscal year 2012 Performance Summary Report, and management's assertions. Our review processes were limited to inquiries and analytical procedures appropriate for an attestation review based upon the criteria specified in the Circular. Specifically, we reviewed FAA's internal controls for performance measures to gain an understanding of how the measures were developed.

During our review, no information came to our attention that the accompanying FAA fiscal year 2012 Drug Control Obligation Summary and Performance Summary reports were not presented in conformity with the ONDCP Circular.

Sincerely,



Louis C. King
Assistant Inspector General for Financial and
Information Technology Audits

Enclosure(s)

cc: DOT Audit Liaison, M-1
FAA Audit Liaison, AAE-100